Related Experiment Videos
Control of lipid disorders in patients with atherosclerotic vascular disease
1Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
Insights
Primary dyslipidemias increase atherosclerotic vascular disease risk. Pharmacologic therapy is indicated when lifestyle changes fail to meet lipid goals, reducing associated morbidity and mortality.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Pharmacology
Background:
- Primary dyslipidemias are linked to increased atherosclerotic vascular disease in coronary, cerebral, and peripheral arteries.
- Nonpharmacologic therapies like diet and exercise are first-line treatments for dyslipidemias.
- Failure to achieve National Cholesterol Education Program (NCEP) therapeutic goals necessitates pharmacologic intervention.
Purpose of the Study:
- To discuss the clinical applications of lipid-lowering drug classes for managing dyslipidemias.
- To outline the selection criteria for pharmacologic agents based on lipid profiles.
- To highlight the role of pharmacologic therapy in reducing atherosclerosis-related morbidity and mortality.
Main Methods:
- Review of current pharmacologic agents for dyslipidemia management.
- Discussion of therapeutic strategies based on NCEP guidelines.
- Analysis of drug class selection based on specific lipid abnormalities (hypercholesterolemia, hypertriglyceridemia, low HDL cholesterol).
Main Results:
- Appropriate pharmacologic therapy significantly reduces morbidity and mortality associated with atherosclerosis.
- Current lipid-lowering agents are highly efficacious in managing dyslipidemias.
- Treatment choice depends on the specific type of dyslipidemia present.
Conclusions:
- Pharmacologic intervention is crucial for patients with dyslipidemias who do not respond to nonpharmacologic measures.
- Effective management of dyslipidemias with available agents can substantially decrease cardiovascular events.
- Understanding the clinical applications of different drug classes is essential for optimal patient care.
Abstract:
The primary dyslipidemias are associated with an increased incidence of atherosclerotic vascular disease in coronary, cerebral, and peripheral vessels. If nonpharmacologic therapy, such as dietary changes and aerobic exercise, fails to achieve the therapeutic goal levels for serum low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides suggested by the National Cholesterol Education Program Adult Treatment Panel, pharmacologic intervention is indicated. The choice of the class of lipid-lowering drug(s) for initial therapy and subsequent therapy depends on the nature of the dyslipidemia, e.g., hypercholesterolemia, hypertriglyceridemia, suppressed HDL cholesterol levels, or combinations of these disturbances in lipid metabolism. Appropriate therapy with the highly efficacious agents currently available significantly reduces the associated morbidity and mortality related to atherosclerosis. The clinical applications of these classes of agents are discussed here.